Cardiac Arrest, Ventricular Arrythmia
Conditions
Brief summary
The aim of this study is to determine whether the prophylactic amiodarone can prevent re-arrest with ventricular shockable rhythm in patients who treated with targeted temperature management after return of spontaneous circulation from cardiac arrest which had been shockable rhythm during CPR.
Detailed description
Patients with cardiac arrest are in high risk of re-arrest during post cardiac arrest care due to vulnerable heart state electrically and hemodynamically. Especially if patients who had experienced shockable rhythms such as ventricular fibrillation or pulseless ventricular tachycardia during CPR, then they are at high risk of developing shockable re-arrest. However until now there has not been any evidence of prophylactic anti arrhythmic drug effect during post cardiac arrest care. Amiodarone is class III anti arrhythmic drug which has been used for conversion of ventricular arrhythmia during CPR. In this study we want to determine whether the prophylactic amiodarone can prevent re-arrest with ventricular shockable rhythm or not.
Interventions
Amiodarone continuous infusion during 24 hours from return of spontaneous circulation.
Sponsors
Won Young Kim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Non traumatic cardiac arrest patients who had VF or pVT during CPR in ER
Exclusion criteria
* age \< 18 yr * pregnancy * non cardiac caused arrest such as hanging * previous amiodarone continuous infusion before radomization * sustained ventricular arrhythmia recurrence after ROSC * extracorporeal membrane oxygenation * contra indication for amiodarone * disagree with this research
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patients with re-arrest by shockable rhythm | 5 days from return of spontaneous circulation | No recurrence of ventricular fibrillation or pulseless ventricular tachycardia |
Other
| Measure | Time frame | Description |
|---|---|---|
| 3 month survivor | 3 months after the time of hospital discharge | mortality |
| 3 months neurological outcome | 3 months after the time of hospital discharge | cerebral performance scales 3, 4 and 5 |
Countries
South Korea
Outcome results
None listed